Skip to content

Elite Pharmaceuticals, Inc.: 10-Q filed 2018-02-09

What Elite Pharmaceuticals, Inc. reported in its quarterly report filed 2018-02-09 (fiscal Q3 2018): 43 published measures, 122 facts as tagged in accession 0001144204-18-006977.

This filing

Form
10-Q (quarterly report)
Filed
2018-02-09
Fiscal period
fiscal Q3 2018
Accession
0001144204-18-006977 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Elite Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2017-12-3132,074,160USD
At 2017-03-3134,311,142USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2017-12-3112,179,784USD
At 2017-03-318,647,105USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2017-12-315,990,419USD
At 2017-03-3125,664,037USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2017-12-317,244,388USD
At 2017-03-3110,594,693USD
At 2016-12-3113,283,362USD
At 2016-03-3111,512,179USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2017-10-01 to 2017-12-31-490,181USD92
2017-04-01 to 2017-12-31-843,758USD275
2016-10-01 to 2016-12-311,666,750USD92
2016-04-01 to 2016-12-317,001,375USD275

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2017-04-01 to 2017-12-31-3,795,644USD275
2016-04-01 to 2016-12-31-3,807,871USD275

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2017-04-01 to 2017-12-31823,545USD275
2016-04-01 to 2016-12-316,391,108USD275

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2017-04-01 to 2017-12-31-378,206USD275
2016-04-01 to 2016-12-31-812,054USD275

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2017-12-31-139,697,324USD
At 2017-03-31-138,853,566USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2017-10-01 to 2017-12-31788,442,363shares92
2017-04-01 to 2017-12-31796,647,284shares275
2016-10-01 to 2016-12-31904,763,177shares92
2016-04-01 to 2016-12-31811,794,206shares275

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2017-10-01 to 2017-12-31795,122,364shares92
2017-04-01 to 2017-12-31803,327,285shares275
2016-10-01 to 2016-12-31910,505,291shares92
2016-04-01 to 2016-12-31817,536,320shares275

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2017-10-01 to 2017-12-310USD/shares92
2017-04-01 to 2017-12-310USD/shares275
2016-10-01 to 2016-12-310USD/shares92
2016-04-01 to 2016-12-310.03USD/shares275

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2017-10-01 to 2017-12-310USD/shares92
2017-04-01 to 2017-12-31-0.01USD/shares275
2016-10-01 to 2016-12-310USD/shares92
2016-04-01 to 2016-12-310USD/shares275

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2017-10-01 to 2017-12-31-1,051,329USD92
2017-04-01 to 2017-12-31-1,051,329USD275
2016-10-01 to 2016-12-31-1,870,114USD92
2016-04-01 to 2016-12-31-1,870,114USD275

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2017-12-319,132,998USD
At 2017-03-319,039,404USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2017-10-01 to 2017-12-31-2,058,961USD92
2017-04-01 to 2017-12-31-6,430,103USD275
2016-10-01 to 2016-12-31-1,722,423USD92
2016-04-01 to 2016-12-31-4,164,583USD275

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2017-12-3114,763,967USD
At 2017-03-3118,412,720USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2017-10-01 to 2017-12-3192,458USD92
2017-04-01 to 2017-12-31245,730USD275
2016-10-01 to 2016-12-3155,563USD92
2016-04-01 to 2016-12-31181,883USD275

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2017-12-314,743,096USD
At 2017-03-313,344,746USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2017-12-311,444,178USD
At 2017-03-311,049,815USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2017-12-311,161,240USD
At 2017-03-31934,059USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2017-10-01 to 2017-12-313,174,586USD92
2017-04-01 to 2017-12-319,242,078USD275
2016-10-01 to 2016-12-312,326,321USD92
2016-04-01 to 2016-12-316,696,079USD275

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2017-12-315,298,943USD
At 2017-03-316,415,966USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2017-10-01 to 2017-12-311,115,625USD92
2017-04-01 to 2017-12-312,811,975USD275
2016-10-01 to 2016-12-31603,898USD92
2016-04-01 to 2016-12-312,531,496USD275

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2017-10-01 to 2017-12-311,419,829USD92
2017-04-01 to 2017-12-313,049,830USD275
2016-10-01 to 2016-12-311,726,751USD92
2016-04-01 to 2016-12-315,755,997USD275

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2017-10-01 to 2017-12-312,514,435USD92
2017-04-01 to 2017-12-316,944,182USD275
2016-10-01 to 2016-12-311,526,183USD92
2016-04-01 to 2016-12-314,312,337USD275

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2017-12-31788,701,827shares
At 2017-03-31927,931,448shares

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2017-12-3117,255,876USD
At 2017-03-3116,466,156USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2017-12-318,122,878USD
At 2017-03-317,426,752USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2017-12-317,704,609USD
At 2017-03-316,419,091USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2017-12-31472,586USD
At 2017-03-31439,927USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2017-12-3139,587USD
At 2017-03-3131,770USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2017-12-311,785,603USD
At 2017-03-31794,628USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2017-12-311,059,396USD
At 2017-03-31468,002USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2017-10-01 to 2017-12-31-1,541,510USD92
2017-04-01 to 2017-12-31-1,895,087USD275
2016-10-01 to 2016-12-31-203,364USD92
2016-04-01 to 2016-12-315,131,261USD275

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2017-10-01 to 2017-12-31-490,181USD92
2017-04-01 to 2017-12-31-843,758USD275
2016-10-01 to 2016-12-311,666,750USD92
2016-04-01 to 2016-12-3127,715,661USD275

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2017-10-01 to 2017-12-31614,994USD92
2017-04-01 to 2017-12-312,068,028USD275
2016-10-01 to 2016-12-31694,321USD92
2016-04-01 to 2016-12-312,060,380USD275

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2017-10-01 to 2017-12-31285,496USD92
2017-04-01 to 2017-12-31696,126USD275
2016-10-01 to 2016-12-31166,602USD92
2016-04-01 to 2016-12-31504,932USD275

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2017-04-01 to 2017-12-31706,759USD275
2016-04-01 to 2016-12-31504,932USD275

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2017-10-01 to 2017-12-31517,451USD92
2017-04-01 to 2017-12-314,535,016USD275
2016-10-01 to 2016-12-311,519,059USD92
2016-04-01 to 2016-12-319,295,844USD275

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2017-04-01 to 2017-12-311,208,100USD275
2016-04-01 to 2016-12-315,770,163USD275

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2017-04-01 to 2017-12-31227,181USD275
2016-04-01 to 2016-12-31-985,619USD275

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2017-04-01 to 2017-12-31-1,117,023USD275
2016-04-01 to 2016-12-312,735,085USD275

Inspect the source

Entity
Elite Pharmaceuticals, Inc. / CIK 0001053369
Captured
2026-09-20T05:17:33.154Z
SEC response SHA-256
b91e0331a01f96870ee44e841f605bd504e1bc784022b77f374cfe93dc363314

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001053369.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))